Stigma in Multiple Sclerosis: The Important Role of Sense of Coherence and Its Relation to Quality of Life

Lydia Grothe1 · Matthias Grothe1 · Judith Wingert1 · Georg Schomerus2 · Sven Speerforck2

Abstract
Background Anticipated and experienced stigma constitute important issues for patients with multiple sclerosis receiving adequate healthcare. Stigma is likely to be associated with lower quality of life in patients with multiple sclerosis, but the underlying mechanisms and contributing factors are unclear.

Methods We conducted a cross-sectional survey among N = 101 patients with a diagnosis of multiple sclerosis in a German outpatient department. Patients completed questionnaires on enacted and self-stigma (SSCI-8), sense of coherence (SOC-L9) and quality of life (MusIQol). Age, sex, disease duration, disability or extent of limitations (EDSS), cognition (SDMT), depression (BDI-II) and fatigue (FSMC) were used as covariates in linear regression and mediation models.

Results 57.3% of patients with MS reported having experienced stigmatization due to MS at least once. Fatigue (b = -0.199, p < 0.001), enacted stigmatization experience (b = -0.627, p = 0.010) and sense of coherence (b = 0.654, p < 0.001) were significant predictors for quality of life. The mediation analysis showed a partial mediation of the association between enacted stigma and quality of life by patients’ sense of coherence (direct effect: b = -1.042, t = -4.021, p < 0.001; indirect effect: b = -0.773, CI = -1.351—-0.339. The association of self-stigma with quality of life was fully mediated by sense of coherence (b = -1.579, CI = -2.954—-0.669).

Conclusion Patients with multiple sclerosis are affected by stigma, which is associated with lower quality of life. Sense of coherence is a potentially important mediator of stigma and represents a promising target to refine existing stigma interventions and improve the quality of life in these patients.

Keywords Stigma · Multiple sclerosis · Quality of life · Sense of coherence

Introduction

Patients with multiple sclerosis (PwMS) often experience negative prejudice, judgment, and exclusion from society because of their disease [1, 2]. This feeling to “have (or [be] believed to have) an attribute that marks them as different and leads them to be devalued in the eyes of others” is conceptualized as stigma [3]. Two different forms of stigmatization can be distinguished – public and self-stigmatization. Labeling and discriminating against persons with allegedly undesirable characteristics due to existing cultural stereotypes and prejudices is called public stigmatization [4]. This public stigma subsequently may lead to self-stigma if those affected recognize prevailing negative stereotypes about their condition and agree with them [2; 5]. Enacted stigma refers to the experience of unfair treatment by others [5]. Stigma therefore is always context-specific and not a fixed attribute or characteristic of a person. It has been shown that the experience of
discrimination and social withdrawal due to stigmatization can strongly affect patients’ self-confidence and self-efficacy. Stigma is a strong stressor in the everyday life of patients with psychiatric disorders like schizophrenia [6] and is also known to reduce the quality of life (QoL) in patients with neurological diseases [7]. The few studies that have investigated experiences with stigma in PwMS have confirmed the link between stigma and QoL. Anagnostouli et al. [8] revealed that both public and self-stigma are associated with impaired QoL. Broersma et al. [9] included sense of coherence (SoC) as another concept and confirmed a positive correlation between the QoL and the SoC of PwMS. The SoC is an important theoretical concept which is closely linked to stigma and QoL. According to Antonovsky, the SoC serves as an individual psychological resource consisting of three components: comprehensibility (the belief that life is structured and explainable), manageability (the belief that one’s own resources are sufficient to cope with future challenges) and meaningfulness (the belief that the challenges are worth striving for) [10]. People with a high SoC are aware of their own resources and are able to resort to them in stressful situations. It has been shown that a high level of SoC is effective in buffering stress. A high SoC is also associated with a better QoL, as patients with a higher SoC are more able to cope with the burden of their disease [11]. In a study by Broersma, a high SoC predicted an increased QoL in PwMS and lower enacted and self-stigmatization [9]. Additionally, Johansson et al. [12] revealed that the SoC is a predictor of depressive symptoms and mood in a cohort of PwMS.

Judging by the complex interactions found in existing literature and theoretical concepts, a more complex relationship between stigma, SoC, and QoL seems conceivable. For example, Świtaj [13] investigated and confirmed the SoC as a mediator between stigmatization experiences and the QoL of patients with mental illnesses. They assumed that the experience of stigmatization reduces patients’ self-esteem, which in turn reduces their SoC. In addition, Lundberg et al. [14] showed that experiences of rejection in patients with mental illnesses are associated with a lower SoC. Due to the stigmatization experiences, patients may perceive increased stress and less support [15], which could eventually negatively influence the SoC [16] and subsequently the QoL.

The aim of this study was to explore stigmatization, SoC and their association with QoL for the first time in a German cohort of PwMS, assuming that stigmatization experiences have a negative impact on the perceived QoL of PwMS, whereas SoC is supposed to have a positive impact on the perceived QoL. Additionally, we investigated whether the SoC mediates the association between stigmatization and QoL in PwMS, with increasing experience of stigmatization leading to a lower SoC, which in turn has a negative effect on the QoL.

Materials and Methods

All 101 PwMS included in the study fulfilled the criteria of multiple sclerosis according to the 2017 McDonald criteria [17]. Exclusion criteria were current or past neurological conditions other than MS and acute clinical relapse within the previous 3 months. Data was taken during routine consultation and from patient records from April to December 2018. The study was approved by the local Ethics committee and all participants gave their written informed consent. The patients completed questionnaires in German on stigmatization experiences (Stigma Scale for Chronic Illnesses 8-item version (SSCI-8)) [18], Sense of Coherence (Sense of Coherence Scale (SOC-L9)) [19] and quality of life (Multiple Sclerosis International Quality of Life Questionnaire (MusIQol)) [20]. The SSCI-8 was developed for people suffering from neurological conditions and is a short 8-item version of the Stigma Scale for Chronic Illnesses (SSCI) by Rao et al. [2]. It measures two dimensions of stigma, enacted and internalized, with a total score calculated from these two subscores. Statistical analyses were performed with IBM SPSS Statistics 21 with the significance level set at \( p < 0.05 \). Once all assumptions of regression testing had been met, ten ordinary multiple regression analyses with the following variables were conducted: age, gender, disease duration, disability or extent of limitations (expanded disability status scale, EDSS) [21], cognition (symbol digit matching task, SDMT) [22], depression (Beck depression inventory, BDI-II) [23], fatigue (Fatigue score for motor and cognition, FSMC) [24], enacted stigma, self-stigma, and SoC. Three mediation analysis were performed using the SPSS macro by Preacher and Hayes [25] with a 95% confidence interval and 10,000 bootstrap samples. To correct for multiple comparisons, we used Bonferroni corrected p-values.

Results

Sample characteristics are shown in Table 1. Participants were mostly female (n = 74; 71.8%), averaged 46.1 years of age, and had a mean disease duration of 10.72 years. Most PwMS had a relapsing remitting course (89.1%), 9.9% a secondary progressive course, and 1.0% a primary progressive course of the disease. A total of 57 PwMS (57.3%) reported having experienced stigmatization due to MS at least once. Of these, 48 (48.5%) patients experienced public or enacted stigmatization, while 40 (40.8%) experienced self-stigmatization.

In the linear regression model, fatigue (b = -0.199), enacted stigmatization experience (b = -0.627) and SoC (b = 0.654) were significant predictors for the overall scale for QoL.
A mediation analysis was performed to examine if the patients’ SoC mediated the association between their stigmatization experiences and their QoL (see Fig. 1). The direct path between stigmatization and QoL remained significant (b = -0.8080, t = -3.95, p < 0.001). However, the indirect effect of both variables also became significant in our mediation model (b = -0.746, CI = -1.174—-0.399). Experiences of stigmatization affected the QoL of PwMS both directly and indirectly, with an indirect effect being mediated through the SoC. Another partial mediation was found when enacted stigmatization was used as the independent variable (b = -0.773, CI = -1.352—-0.339). However, if self-stigma was used as independent variable, the direct path became insignificant and the relationship between self-stigma and QoL was completely mediated by the SoC (b = -1.579, CI = -2.954—-0.669).

* p < .05, ** p < .01, *** p < .001, n.s. not significant, SoC Sense of Coherence, QoL Quality of Life

### Discussion

Stigmatization experience affected the QoL in PwMS. This applies both to patients’ overall stigmatization experiences and to enacted and self-stigma, which had various effects on different QoL subscales in our cohort. In general, the participants in our study experienced only a low level of stigmatization. This is consistent with results from previous studies with PwMS, in which the patients also reported a low to moderate overall stigmatization experience [9]. Nevertheless, stigmatization experience were significantly related to QoL. The more stigmatized PwMS felt, the lower was their perceived QoL, which is consistent with the results of Anagnostouli et al. [8]. A more detailed view of the subscales of our QoL questionnaire revealed distinct associations: enacted stigmatization affected the total QoL score as well as the three subscores (activities of daily living, the experience of symptoms and rejection), whereas self-stigma only affected the rejection scale. The different relationships between enacted and self-stigmatization were also investigated by Anagnostouli et al. [8]. In their study, they used a different questionnaire, the Multiple Sclerosis Quality of Life 54, to measure QoL. However, its subdimensions are summarized to either physical or mental health, which at least in part correspond to the dimensions of daily life activities and psychological well-being used in this study [20]. Anagnostouli et al. [8] showed that each dimension of stigmatization correlated negatively with both physical and mental health. They also report a significant impact of enacted stigmatization on physical health and of self-stigmatization on both physical and mental health. Our data is more compatible with that of Broersma et al. [9], according to which enacted stigmatization is predominantly associated with activities of daily living. The subscales activities of daily living and symptoms both refer to patients’ physical limitations. It can be assumed that PwMS with more physical limitations also feel more exposed to negative stereotypes in their social environment due to a more visible impact of MS. On the other hand, the subscales dealing with the relationships with friends, family or the health care system (HCS) seem to be more robust against public stigmatization. The patients apparently have confided in family and friends as well as in the HCS. They do not expect discriminatory treatment by them and therefore do not expect stigmatization. In contrast, the experience of stigmatization feel rejected by their surroundings with a negative effect...
Table 2  Regression coefficients (and standard errors) showing the predictors of quality of life (QoL) and its subscales in patients with MS

|                      | QoL – total | Activities of daily living | Psychological well-being | Symptoms | Relationships with friends | Relationships with family | Sentimental and sexual life | Coping | Rejection | Relationships with health care system |
|----------------------|------------|----------------------------|--------------------------|----------|---------------------------|---------------------------|-----------------------------|--------|----------|------------------------------------|
| F                    |            | F (3, 86) = 82.875***     | F (4, 85) = 66.789***    |          | F (4, 85) = 32.664***     | F (4, 85) = 52.481***     | F (1, 88) = 17.191***      | F (2, 87) = 8.417***       | F (2, 87) = 21.820***     | F (3, 86) = 14.267***        | F (1, 88) = 18.306***       |
| R²                   | 0.743      | 0.759                      | 0.712                     |          | 0.163                     | 0.162                     | 0.334                       | 0.474   | 0.332     | 0.172                             | 0.05                       |
| Constant             | 62.521 (5.367) | 119.728 (3.823) | 57.655 (11.471) | 106.963 (5.124) | 26.369 (10.330) | 35.236 (11.044) | -13.503 (13.002) | 60.133 (12.707) | 109.296 (3.882) | 92.030 (1.333) |                               |
| Gender               | 0.059      | 0.065                      | 5.795 (2.869)            | 5.304 (2.364) | 0.014                     | 0.011                     | 0.093                       | -0.035  | -0.016    | -0.005                            |                               |
| Age                  | 0.029      | -0.061                     | 0.059                     | -0.004   | 0.119                     | 0.084                     | -0.066                       | 0.058   | 0.085     | 0.071                             |                               |
| Duration             | -0.062     | -0.066                     | -0.004                    | -0.073   | 0.016                     | 0.073                     | -0.015                       | -0.005  | -0.080    | -0.045                            |                               |
| SDMT<sup>a</sup>     | 0.057      | -0.010                     | -0.031                    | -0.079   | 0.015                     | 0.171                     | 0.460 (0.162)                | -0.016  | -0.056    | -0.072                            |                               |
| EDSS<sup>b</sup>     | -0.029     | -4.531 (0.602)***          | -0.051                    | 0.060    | 0.114                     | 2.244 (1.043)             | *                            | 0.014   | -0.101    | -0.144                            | 0.092                       |
| BDF                  | -0.123     | -0.494                     | -0.713 (0.271)            | *        | -0.449 (0.191)            | 0.073                     | 0.004                       | -0.063  | -0.940 (0.248)***                | -0.422 (0.187)               | 0.176                       |
| F<sub>SMC</sub><sup>c</sup> | -0.199 (0.034)*** | -0.367 (0.071)*** | -0.176 (0.080)           | -0.436 (0.067)   | 0.035                     | -0.103                    | -0.158                       | 0.034   | -0.111    | 0.003                             |                               |
| Stigma enacted       | -0.627 (0.237) | *                        | 0.032                     | -1.232 (0.403)*** | -0.189                    | -0.003                    | -0.081                       | 0.029   | -1.129 (0.477)        | -2.301 (0.829)               | 0.111                       |
| Stigma internalized  | -0.303     | 0.007                      | -0.134                    | -0.004   | 0.104                     | 0.156                     | 0.042                       | -0.117  | -0.053    |                                  |                               |
| SoCe<sup>d</sup>     | 0.654 (0.078) | 0.107                     | 0.605 (0.192)             | -0.034   | 0.835 (0.201)            | 0.729 (0.209)            | 1.244 (0.222)               | 0.659 (0.216) | 0.121     | 0.571 (0.133)                     |                               |

<sup>a</sup>Symbol digit matching task
<sup>b</sup>Expanded disability status scale
<sup>c</sup>Beck depression inventory
<sup>d</sup>Fatigue score for motor and cognition
<sup>e</sup>Sense of Coherence

*p < .05, **p < .01, ***p < .001
on their QoL. This assumption is mirrored by the association of self-stigma with the expectation of being rejected.

A significant positive correlation between the SoC and the QoL was found. This result is in line with a large number of studies on the SoC in various chronic diseases, such as those compiled by Eriksson and Lindström in their review on this topic [26]. These results are largely consistent with the results of Broersma et al. [9]. In their study, they showed significant associations between the SoC and all subscales of the QoL. In our study, the SoC had an impact on almost all subscales of the QoL except on the activities of daily living, symptoms and rejection. Interestingly, these are exactly the scales that were influenced by stigma experience.

It seems that the domains affected by enacted stigmatization may be less related to patients’ SoC, perhaps because the SoC is not able to buffer the negative impact of discriminatory experiences. Similarly, Broersma et al. [9] were able to show that the SoC is usually only a predictor of QoL if enacted stigmatization was not included. If the patients have already agreed to the negative stereotypes about themselves and thus experienced self-stigma, this can be influenced by the SoC, because of its function as an internal resource.

A high experience of stigmatization was associated with a lower SoC, which in turn was related to lower QoL for PwMS. Conversely, a lower level of stigmatization experience was associated with a higher SoC, which was related to higher QoL. These results are comparable with those of Świtaj [13], who found that SoC acted as a mediator between self-stigmatization and quality of life in patients with mental illness.

In addition to the mediation of stigma experiences via the SoC, the direct path from stigma experience to QoL remained significant. In contrast, the relationship between internalized stigmatization and the QoL was completely mediated by the SoC. A possible explanation would be that experienced discrimination is imposed on patients from their social environment and is related to multiple dimensions of QoL, such as activities of daily living, and are therefore not fully mediated by the SoC. In accordance with this speculation, the relationship between self-stigma and QoL, might be completely mediated by the SoC, since internalized stigma and SoC probably represent partially intersecting cognitive constructs, especially ‘manageability’. As Corrigan et al. [27] have outlined, reduced self-esteem and self-efficacy are immanent consequences of internalized stigma and therefore closely related to the perceived manageability as part of the SoC.

**Limitations**

Some limitations concerning this study must be considered. First, as in most previous studies, this applies only to the sample. The present study is a cross-sectional sample with a relatively small sample size. However, this is the first study ever regarding stigma in PwMS in Germany. Especially the mediation analysis has never been performed before in this context. It is therefore difficult to draw causal conclusions from the data with absolute certainty. The next step would be to carry out a longitudinal study in which the participants are accompanied over several measurement points. Furthermore, all PwMS were patients of the special outpatient clinic for MS in a German university medical center. This may be an explanation...
for the rather low experience of stigmatization. PwMS who feel strongly stigmatized tend to avoid medical services [28] and would therefore not attend medical consultations.

A second point is the difficulty of comparing scales used in other studies to measure stigmatization experience and QoL. Many different questionnaires were used across different studies. Additionally, the analyses often focused on only one subscale of either the stigmatization experience or the QoL, so that an exact comparability with the present study was not always given.

**Conclusion**

Results from this study show that stigmatization experience and the SoC in PwMS are related with their QoL. Even if the average stigmatization experience was low, the relationship with both QoL and SoC is relevant. In addition, SoC could be found as a mediator between the stigmatization experience and the QoL.

The fact that PwMS are affected by stigmatization has already been shown in previous studies and was confirmed here. On the other hand, SoC and its effects on MS have hardly been investigated so far, and the mediating function of SoC has not been previously demonstrated in any study in PwMS. It provides an indication of the processes by which the stigmatization experience is mediated. This can be a starting point for the development of interventions to improve the QoL in PwMS. To strengthen the SoC in PwMS, both behavioral and perceptual processes should be addressed [29]. This may help PwMS to better manage stigmatization and thus achieve a higher QoL, while a higher SoC can also counteract the development of depression [30].

Since stigmatization affects not only the QoL of PwMS, but also their willingness to seek medical help or to continue to participate in social life, further studies should investigate whether these processes are also mediated through the SoC and if the SoC is affected by anti-stigma interventions. If this were the case, appropriate interventions could be developed or refined to help and support those affected. There is also evidence that the stigmatization experience in PwMS is associated with depression [30] and disability [9]. A link was also found between SoC and fatigue [12] and SoC and depression [31]. These individual correlations must be examined more closely in subsequent studies and integrated into an overall model. Not only the direct effects should be measured, but also the possibility of moderation and mediation effects should be considered. In further steps, data from longitudinal studies should be collected to uncover possible causalities.

**Acknowledgements** The authors wish to thank Anya Leonhard for her help with the manuscript and the patients for making the study possible. No funding was received for conducting this study.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Declarations**

**Ethical approval** All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Conflict of interest** L.G., J.W., G.S. and S.S. have no conflicts of interest to declare that are relevant to the content of this article. M.G. received honoraria and travel reimbursements for attending meetings from Biogen, Celgene, Merck Serono, Novartis, Roche, Sanofi-Genzyme, TEVA. His research is funded by German Ministry for Education and Research (BMBF), Merck Serono and Novartis. None resulted in a conflict of interest.

**Informed consent** Informed consent was obtained from all participants included in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Lekas HM, Siegel K, Leider J. Felt and Enacted Stigma Among HIV/HCV-Coinfected Adults: The Impact of Stigma Layering. Qual Health Res. 2011;21:1205–19.
2. Rao D, Choi SW, Victorson D, et al. Measuring stigma across neurological conditions: the development of the stigma scale for chronic illness (SSCI). Qual Life Res. 2009;18:585–95.
3. Major B, O’Brien LT. The Social Psychology of Stigma. Annu Rev Psychol. 2005;56:393–421.
4. Schomerus G, Angermeyer M. Stigmatisierung psychisch Kranker. Psychiatrie und Psychotherapie up2date. 2011;5:345–356.
5. Gray AJ. Stigma in psychiatry. J R Soc Med. 2002;95:72–6.
6. Rüscher N, Corrigan PW, Powell K, et al. A stress-coping model of mental illness stigma: II. Emotional stress responses, coping behavior and outcome. Schizophrenia Research. 2009;110:65–71.
7. Jacoby A. Stigma, epilepsy, and quality of life. Epilepsy Behav. 2002;3:10–20.
8. Anagnostouli M, Katsavos S, Artemiadis A, et al. Determinants of stigma in a cohort of helenic patients suffering from multiple sclerosis: a cross-sectional study. BMC Neurol. 2016;16:1–10.
9. Broersma F, Oeseburg B, Dijkstra J, Wynia K. The impact of self-perceived limitations, stigma and sense of coherence on quality of life in multiple sclerosis patients: results of a cross-sectional study. Clin Rehabil. 2018;32:536–45.
10. Antonovsky H, Sagy S. The development of a sense of coherence and its impact on responses to stress situations. J Soc Psychol. 1986;126:213–26.
11. Hsiao CY, Lu HL, Tsai YF. Effect of family sense of coherence on internalized stigma and health-related quality of life among individuals with schizophrenia. Int J Ment Health Nurs. 2018;27:138–46.

12. Johansson S, Gottberg K, Kierkegaard M, Ytterberg C. Variations in and predictors of the occurrence of depressive symptoms and mood symptoms in multiple sclerosis: a longitudinal two-year study. BMC Neurol. 2016;16:1–9.

13. Świtaj P, Grygiel P, Chrostek A, Nowak I, Wciórka J, Anczewska M. The relationship between internalized stigma and quality of life among people with mental illness: are self-esteem and sense of coherence sequential mediators? Qual Life Res. 2017;26:2471–8.

14. Lundberg B, Hansson L, Wentz E, Björkman T. Are stigma experiences among persons with mental illness, related to perceptions of self-esteem, empowerment and sense of coherence? J Psychiatr Ment Health Nurs. 2009;16:516–22.

15. Korkmaz G, Küçük L. Internalized Stigma and Perceived Family Support in Acute Psychiatric In-Patient Units. Arch Psychiatr Nurs. 2016;30:55–61.

16. Wolff AC, Ratner PA. Stress, Social Support, and Sense of Coherence. West J Nurs Res. 1999;21:182–97.

17. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17:162–73.

18. Molina Y, Choi SW, Cell D, Rao D. The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions. Int J Behav Med. 2013;20:450–60.

19. Schumacher J, Wilz G, Gunzelmann T, Brährle E. Die Sense of Coherence Scale von Antonovsky - Teststatistische Überprüfung in einer repräsentativen Bevölkerungsstichprobe und Konstruktion einer Kurzskala. PPM: Psychotherapie Psychosomatik Psychiatrie Medizinische Psychologie. 2000;50:472–482.

20. Flachenecker P, Vogel U, Simeoni MC, Augier P, Rieckmann P. MusiQol: Internationaler Fragebogen zur Erfassung der Lebensqualität bei Multipler Sklerose: Validierungsergebnisse der deutschen Subpopulation im internationalen Vergleich. Nerve- narzt. 2011;82:1281–9.

21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1982;33:1444–52.

22. Smith A. Symbol Digit Modalities Test: Manual I. Los Angeles: Western Psychological Services; 1982.

23. Hauzenberger M, Keller F, Kühn C. Beck Depression-Inventar (BDI-II). Revision. Frankfurt/Main: Harcourt Test Services; 2006.

24. Penner I, Raselli C, Stöcklin M, Opwis K, Kappos L, Calabrese P. The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler J. 2009;15:1509–17.

25. Hayes AF. Beyond Baron and Kenny: Statistical Mediation Analysis in the New Millennium. Commun Monogr. 2009;76:408–20.

26. Eriksson M, Lindstrom B, Antonovsky’s sense of coherence scale and its relation with quality of life: a systematic review. J Epidemiol Community Health. 2007;61:938–44.

27. Schomerus G, Angermeyer MC. Stigma and its impact on help-seeking for mental disorders: what do we know? Epidemiol Psychiatri Soc. 2008;17:31–7.

28. Super S, Wagemakers MAE, Picavet HSJ, Verkooijen KT, Koelen MA. Strengthening sense of coherence: opportunities for theory building in health promotion. Health Promot Int. 2016;31:869–78.

29. Cadden MH, Arnett PA, Tyry TM, Cook JE. Judgment hurts: The psychological consequences of experiencing stigma in multiple sclerosis. Sociol Sci Med. 2018;208:158–64.

30. Gottberg K, Einarsson U, Fredriksson S, von Koch L, Holmqvist LW. A population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence. J Neurol Neurosurg Psychiatry. 2007;78:60–5.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.